Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Chia Wen Ko"'
Autor:
Heng Li, Manuela Buzoianu, Adrijo Chakraborty, Li Ming Dong, Chia-Wen Ko, Xuefeng Li, Nelson Lu, Yanping Qu, Yunling Xu, Xu Yan
Publikováno v:
Therapeutic Innovation & Regulatory Science. 57:464-466
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc42eadeffc62cdd234eb09f69041db2
https://doi.org/10.1007/s43441-022-00456-3
https://doi.org/10.1007/s43441-022-00456-3
Autor:
Richard Pazdur, Ann T. Farrell, Marjorie Shapiro, Christopher M. Sheth, Jiang Liu, Lei Nie, Donna Przepiorka, Kelly J. Norsworthy, Charles Jewell, Antonina Aydanian, Pedro L. Del Valle, Jee Eun Lee, Chia-Wen Ko, Emily Y. Jen
Supplemental Table 1 describes the adverse events with corresponding risk differences between treatment arms during induction of pivotal trial ALFA-0701.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bd7a67b15c996ac2b4ce4780a377946
https://doi.org/10.1158/1078-0432.22470144
https://doi.org/10.1158/1078-0432.22470144
Autor:
Richard Pazdur, Ann T. Farrell, Marjorie Shapiro, Christopher M. Sheth, Jiang Liu, Lei Nie, Donna Przepiorka, Kelly J. Norsworthy, Charles Jewell, Antonina Aydanian, Pedro L. Del Valle, Jee Eun Lee, Chia-Wen Ko, Emily Y. Jen
On September 1, 2017, the FDA granted approval for gemtuzumab ozogamicin (Mylotarg; Pfizer Inc.) in combination with daunorubicin and cytarabine and as a monotherapy for the treatment of adult patients with newly diagnosed CD33-positive acute myeloid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a3057e773121d0976ff70e8b3c1217f
https://doi.org/10.1158/1078-0432.c.6527439.v1
https://doi.org/10.1158/1078-0432.c.6527439.v1
Autor:
Richard Pazdur, Ann T. Farrell, Marjorie Shapiro, Christopher M. Sheth, Jiang Liu, Lei Nie, Donna Przepiorka, Kelly J. Norsworthy, Charles Jewell, Antonina Aydanian, Pedro L. Del Valle, Jee Eun Lee, Chia-Wen Ko, Emily Y. Jen
Supplemental Table 4 and the accompanying text describe the grouped terms used for the adverse reactions described in Table 2 and the reasons for using grouped terms.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bfa00162775f4396f1aa89b2c0e5fca
https://doi.org/10.1158/1078-0432.22470135.v1
https://doi.org/10.1158/1078-0432.22470135.v1
Autor:
Richard Pazdur, Ann T. Farrell, Marjorie Shapiro, Christopher M. Sheth, Jiang Liu, Lei Nie, Donna Przepiorka, Kelly J. Norsworthy, Charles Jewell, Antonina Aydanian, Pedro L. Del Valle, Jee Eun Lee, Chia-Wen Ko, Emily Y. Jen
Supplemental Table 2 describes the adverse events with corresponding risk differences between treatment arms during consolidation 1 of pivotal trial ALFA-0701.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2cceacb4b09d64994c9590265576d3f
https://doi.org/10.1158/1078-0432.22470141
https://doi.org/10.1158/1078-0432.22470141
Autor:
Richard Pazdur, Ann T. Farrell, Qing Zhou, Ping Zhao, Pengfei Song, Deborah Schmiel, Tiffany K. Ricks, Nitin Mehrotra, Susan Kirshner, Robert C. Kane, Candace Gomez-Broughton, Brenda J. Gehrke, Haw-Jyh Chiu, Reyes Candau-Chacon, Carolyn L. Yancey, Albert Deisseroth, Chia-Wen Ko, Donna Przepiorka
Preferred Terms included in grouped terms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04eb5dd9d2864438c9fd3c493117694a
https://doi.org/10.1158/1078-0432.22457625.v1
https://doi.org/10.1158/1078-0432.22457625.v1
Autor:
Richard Pazdur, Ann T. Farrell, Marjorie Shapiro, Christopher M. Sheth, Jiang Liu, Lei Nie, Donna Przepiorka, Kelly J. Norsworthy, Charles Jewell, Antonina Aydanian, Pedro L. Del Valle, Jee Eun Lee, Chia-Wen Ko, Emily Y. Jen
Supplemental Table 3 describes the adverse events with corresponding risk differences between treatment arms during consolidation 2 of pivotal trial ALFA-0701.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60239a2a0c9573ca130b251dacba13e0
https://doi.org/10.1158/1078-0432.22470138.v1
https://doi.org/10.1158/1078-0432.22470138.v1
Autor:
Kelly J. Norsworthy, Xin Gao, Chia-Wen Ko, E. Dianne Pulte, Jiaxi Zhou, Yutao Gong, Yuan Li Shen, Jonathon Vallejo, Thomas E. Gwise, Rajeshwari Sridhara, Albert B. Deisseroth, Ann T. Farrell, R. Angelo de Claro, Gideon M. Blumenthal, Richard Pazdur
Publikováno v:
J Clin Oncol
PURPOSE To explore trial-level and patient-level associations between response (complete remission [CR] and CR + CR with incomplete hematologic [CRi] or platelet [CRp] recovery), event-free survival (EFS), and overall survival (OS) in newly diagnosed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a53b9bf2442dcabe3676aad1a47631d3
https://pubmed.ncbi.nlm.nih.gov/35007124
https://pubmed.ncbi.nlm.nih.gov/35007124
Autor:
Yuching Yang, Sriram Subramaniam, Donna Przepiorka, Lei Nie, Amy E. McKee, Richard Pazdur, Lian Ma, Stacy S. Shord, Ann T. Farrell, Chia-Wen Ko, Yvette L. Kasamon
Publikováno v:
The Oncologist
In April 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to midostaurin for the treatment of adult patients with aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm, and mast cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db41fbcfb9ee211dc171ac26d33f7d41
https://doi.org/10.1634/theoncologist.2018-0222
https://doi.org/10.1634/theoncologist.2018-0222
Publikováno v:
Statistical Methods in Medical Research. 28:1293-1310
Meta-analysis of interventions usually relies on randomized controlled trials. However, when the dominant source of information comes from single-arm studies, or when the results from randomized controlled trials lack generalization due to strict inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0614db994d0741b2f6a580361bfd1b26
https://doi.org/10.1177/0962280218754928
https://doi.org/10.1177/0962280218754928